Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Obesity resistant mechanisms in the Lean polygenic mouse model as indicated by liver transcriptome and expression of selected genes in skeletal muscle.

Simončič M, Režen T, Juvan P, Rozman D, Fazarinc G, Fievet C, Staels B, Horvat S.

BMC Genomics. 2011 Feb 3;12:96. doi: 10.1186/1471-2164-12-96.

2.

The farnesoid X receptor regulates adipocyte differentiation and function by promoting peroxisome proliferator-activated receptor-gamma and interfering with the Wnt/beta-catenin pathways.

Abdelkarim M, Caron S, Duhem C, Prawitt J, Dumont J, Lucas A, Bouchaert E, Briand O, Brozek J, Kuipers F, Fievet C, Cariou B, Staels B.

J Biol Chem. 2010 Nov 19;285(47):36759-67. doi: 10.1074/jbc.M110.166231. Epub 2010 Sep 17.

3.

Kruppel-like factor KLF10 is a link between the circadian clock and metabolism in liver.

Guillaumond F, Gréchez-Cassiau A, Subramaniam M, Brangolo S, Peteri-Brünback B, Staels B, Fiévet C, Spelsberg TC, Delaunay F, Teboul M.

Mol Cell Biol. 2010 Jun;30(12):3059-70. doi: 10.1128/MCB.01141-09. Epub 2010 Apr 12.

4.

The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.

Tancevski I, Demetz E, Eller P, Duwensee K, Hoefer J, Heim C, Stanzl U, Wehinger A, Auer K, Karer R, Huber J, Schgoer W, Van Eck M, Vanhoutte J, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A.

PLoS One. 2010 Jan 15;5(1):e8722. doi: 10.1371/journal.pone.0008722.

5.

Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.

Julve J, Escolà-Gil JC, Rotllan N, Fiévet C, Vallez E, de la Torre C, Ribas V, Sloan JH, Blanco-Vaca F.

Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):232-8. doi: 10.1161/ATVBAHA.109.198226. Epub 2009 Nov 12. Erratum in: Arterioscler Thromb Vasc Biol. 2010 May;30(5):1070.

6.

Combination therapy of statins and fibrates in the management of cardiovascular risk.

Fiévet C, Staels B.

Curr Opin Lipidol. 2009 Dec;20(6):505-11. doi: 10.1097/MOL.0b013e328332e9ef. Review.

7.

Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver.

Lalloyer F, Pedersen TA, Gross B, Lestavel S, Yous S, Vallez E, Gustafsson JA, Mandrup S, Fiévet C, Staels B, Tailleux A.

Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1488-95. doi: 10.1161/ATVBAHA.109.189506. Epub 2009 Jul 10.

8.

Efficacy of peroxisome proliferator-activated receptor agonists in diabetes and coronary artery disease.

Fiévet C, Staels B.

Curr Atheroscler Rep. 2009 Jul;11(4):281-8. Review.

PMID:
19500491
9.

Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis.

Brunham LR, Singaraja RR, Duong M, Timmins JM, Fievet C, Bissada N, Kang MH, Samra A, Fruchart JC, McManus B, Staels B, Parks JS, Hayden MR.

Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):548-54. doi: 10.1161/ATVBAHA.108.182303. Epub 2009 Feb 5.

10.

The thyromimetic T-0681 protects from atherosclerosis.

Tancevski I, Wehinger A, Demetz E, Hoefer J, Eller P, Huber E, Stanzl U, Duwensee K, Auer K, Schgoer W, Kuhn V, Fievet C, Stellaard F, Rudling M, Foeger B, Patsch JR, Ritsch A.

J Lipid Res. 2009 May;50(5):938-44. doi: 10.1194/jlr.M800553-JLR200. Epub 2008 Dec 22.

11.

Liver X receptor modulators: effects on lipid metabolism and potential use in the treatment of atherosclerosis.

Fiévet C, Staels B.

Biochem Pharmacol. 2009 Apr 15;77(8):1316-27. doi: 10.1016/j.bcp.2008.11.026. Epub 2008 Dec 3. Review.

PMID:
19101522
12.

Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis.

MacDonald ML, van Eck M, Hildebrand RB, Wong BW, Bissada N, Ruddle P, Kontush A, Hussein H, Pouladi MA, Chapman MJ, Fievet C, van Berkel TJ, Staels B, McManus BM, Hayden MR.

Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):341-7. doi: 10.1161/ATVBAHA.108.181099. Epub 2008 Dec 18.

13.

Rosiglitazone modifies HDL structure and increases HDL-apo AI synthesis and catabolic rates.

Carreón-Torres E, Rendón-Sauer K, Monter-Garrido M, Toledo-Ibelles P, Gamboa R, Menjivar M, López-Marure R, Luc G, Fievet C, Cruz D, Vargas-Alarcón G, Pérez-Méndez O.

Clin Chim Acta. 2009 Mar;401(1-2):37-41. doi: 10.1016/j.cca.2008.11.003. Epub 2008 Nov 12.

PMID:
19036342
14.

Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.

Mansouri RM, Baugé E, Gervois P, Fruchart-Najib J, Fiévet C, Staels B, Fruchart JC.

Circ Res. 2008 Aug 29;103(5):450-3. doi: 10.1161/CIRCRESAHA.108.179861. Epub 2008 Jul 24.

15.

Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ABCG5/G8.

Calpe-Berdiel L, Rotllan N, Fiévet C, Roig R, Blanco-Vaca F, Escolà-Gil JC.

J Lipid Res. 2008 Sep;49(9):1904-11. doi: 10.1194/jlr.M700470-JLR200. Epub 2008 May 28.

16.

Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5'-triphosphate-binding cassette transporter 1 expression.

Tancevski I, Wehinger A, Demetz E, Eller P, Duwensee K, Huber J, Hochegger K, Schgoer W, Fievet C, Stellaard F, Rudling M, Patsch JR, Ritsch A.

Endocrinology. 2008 Jul;149(7):3708-12. doi: 10.1210/en.2007-1387. Epub 2008 Apr 3.

17.

Estimating the effect of protected lands on the development and conservation of their surroundings.

McDonald RI, Yuan-Farrell C, Fievet C, Moeller M, Kareiva P, Foster D, Gragson T, Kinzig A, Kuby L, Redman C.

Conserv Biol. 2007 Dec;21(6):1526-36. doi: 10.1111/j.1523-1739.2007.00799.x.

PMID:
18173476
18.

Absence of stearoyl-CoA desaturase-1 ameliorates features of the metabolic syndrome in LDLR-deficient mice.

MacDonald ML, Singaraja RR, Bissada N, Ruddle P, Watts R, Karasinska JM, Gibson WT, Fievet C, Vance JE, Staels B, Hayden MR.

J Lipid Res. 2008 Jan;49(1):217-29. Epub 2007 Oct 24.

19.

S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects.

Carmona MC, Louche K, Lefebvre B, Pilon A, Hennuyer N, Audinot-Bouchez V, Fievet C, Torpier G, Formstecher P, Renard P, Lefebvre P, Dacquet C, Staels B, Casteilla L, Pénicaud L; Consortium of the French Ministry of Research and Technology.

Diabetes. 2007 Nov;56(11):2797-808. Epub 2007 Aug 17.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk